Skip to main content
LUMIBIRD logo

LUMIBIRD — Investor Relations & Filings

Ticker · LBIRD ISIN · FR0000038242 LEI · 969500MLJC3ZSZP4L019 PA Manufacturing
Open in API
Filings indexed 560 across all filing types
Latest filing 2023-11-15 Regulatory Filings
Country FR France
Listing PA LBIRD

About LUMIBIRD

https://www.lumibird.com/en/

LUMIBIRD is a leading specialist in laser technologies with over 50 years of experience. The company designs and manufactures high-performance lasers based on its expertise in three key technologies: solid-state lasers, fiber lasers, and laser diodes. It operates through two primary divisions. The Photonics division provides advanced laser solutions for applications in defense, space, environmental monitoring (including Lidar sensors), industrial manufacturing, and scientific research. The Medical division offers innovative ophthalmological and medical solutions, ranging from diagnostic equipment to laser treatment systems, through brands such as Quantel Medical and Ellex.

Recent filings

Filing Released Lang Actions
LUMIBIRD : QUANTEL MEDICAL PARMI LES PREMIERS LAUREATS DE L’APPEL A PROJET « IMAGERIE MEDICALE » DE FRANCE 2030
Regulatory Filings Classification · 100% confidence The document is a press release dated November 15, 2023, announcing that Quantel Medical (a subsidiary of LUMIBIRD) has been selected as a laureate for the 'Medical Imaging' call for projects under France 2030, receiving €2.8 million in public aid. This announcement details a specific project (HoloDoppler), its goals, market potential, and the funding received. This type of announcement, focusing on specific strategic developments, funding awards, or significant operational updates outside of routine financial reporting (like earnings or annual reports), best fits the 'Regulatory Filings' (RNS) category as a general regulatory/corporate announcement, or potentially 'Capital/Financing Update' (CAP) due to the significant grant funding. However, since it is primarily an announcement of a project selection and grant award rather than a direct financing activity like issuing debt or equity, RNS is the most appropriate general category for non-standard corporate news releases. Given the context of a press release announcing a government grant for R&D, RNS serves as the best fit among the provided options for a significant, non-periodic corporate event announcement.
2023-11-15 French
LUMIBIRD : QUANTEL MEDICAL ONE OF THE FIRST WINNERS OF THE FRANCE 2030 “MEDICAL IMAGING” CALL FOR PROJECTS
M&A Activity Classification · 99% confidence The document is a press release dated November 15, 2023, announcing that Quantel Medical's 'HoloDoppler' project received €2.8m in public funding from the France 2030 program, managed by Bpifrance. This announcement details a specific corporate development related to R&D funding and partnership, which falls under corporate financing or strategic updates. It is not a full annual report (10-K), an earnings release (ER), or a formal regulatory filing like a DIRS or MRQ. Since it specifically concerns receiving public funding for a project, it aligns best with 'Capital/Financing Update' (CAP), as it involves securing external capital/grants for development. It is too specific for a general Regulatory Filing (RNS) and does not fit any other category.
2023-11-15 English
LUMIBIRD : nombre d'actions au 31 octobre 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is titled 'Informations relatives au nombre total de droits de vote et d'actions' (Information relating to the total number of voting rights and shares) and explicitly references French regulatory articles (Code de commerce and Règlement général de l'Autorité des Marchés Financiers). It provides a table detailing the total number of shares, the actual number of voting rights, and the theoretical number of voting rights as of a specific date (October 31, 2023). This content directly relates to the official disclosure of voting rights and capital structure components, which aligns best with the 'Declaration of Voting Results & Voting Rights Announcements' (DVA) category, as it is a formal declaration regarding voting rights.
2023-11-13 French
LUMIBIRD : CHIFFRE D’AFFAIRES DES 9 PREMIERS MOIS 2023 A 139,0 M€ (+11%)
Earnings Release Classification · 100% confidence The document is titled 'CHIFFRE D'AFFAIRES DES 9 PREMIERS MOIS 2023' (Revenue for the first 9 months of 2023) and provides detailed, non-audited financial figures broken down by quarter (T1, T2, T3) and cumulative 9-month period, segmented by division (Photonique, Médical) and geography. It also includes management commentary on performance and outlook for Q4. This structure is characteristic of a periodic financial report covering a period shorter than a full year, specifically an interim or quarterly report. Since it covers 9 months, it aligns best with the 'Interim / Quarterly Report' definition (IR). It is not a full Annual Report (10-K), an Earnings Release (ER, which is usually just the highlights), or a Call Transcript (CT). 9M 2023
2023-10-24 French
LUMIBIRD: REVENUES FOR THE FIRST 9 MONTHS OF 2023: €139.0M (+11%)
Earnings Release Classification · 100% confidence The document explicitly reports financial results for a specific period: 'REVENUES FOR THE FIRST 9 MONTHS OF 2023: €139.0M (+11%)'. It includes detailed tables breaking down revenues by quarter and segment, and provides forward-looking guidance for Q4 and the full year 2023. This structure is characteristic of an Interim/Quarterly Report (IR), which covers a period shorter than a full year. It is not a full Annual Report (10-K), nor is it just a brief Earnings Release (ER) announcing highlights; it contains substantial detail. It is also not a Call Transcript (CT) or an Investor Presentation (IP), but a formal financial summary. 9M 2023
2023-10-24 English
LUMIBIRD : nombre d'actions au 30 septembre 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document text is very short (839 characters) and presents a table detailing the 'Informations relatives au nombre total de droits de vote et d'actions' (Information relating to the total number of voting rights and shares) as required by French regulations (Code de commerce and AMF General Regulation). This specific disclosure, which updates the total number of shares and voting rights as of a specific date (September 30, 2023), is a mandatory regulatory filing in France. It does not fit the definition of a full Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). Since it is a specific regulatory disclosure concerning share capital structure and voting rights, and given the options, it is best classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if the context implied a change leading to this disclosure. However, the structure strongly suggests a routine regulatory disclosure mandated by the AMF. Given the options, RNS is the most appropriate fallback for specific, non-core financial disclosures that don't match other categories, although it is a very specific type of regulatory notice. Since there is no specific code for 'Total Voting Rights Disclosure', RNS serves as the best fit for a mandatory regulatory announcement.
2023-10-09 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.